BACKGROUND: Radiotherapy (RT) in the pediatric brain tumor population causes late neurocognitive effects. In the current study, the authors investigated associations between clinical and dosimetric risk factors and memory outcomes in a cohort of patients treated with proton radiotherapy (PRT). METHODS: A total of 70 patients (median age at PRT, 12.1 years [range, 5.0-22.5 years]) who were treated with PRT were identified with baseline and follow-up evaluations of visual and verbal memory (Children's Memory Scale and the third edition of the Wechsler Memory Scale). Whole-brain as well as bilateral hippocampal and temporal lobe contours were delineated for the calculation of dosimetric indices. Multivariate analyses were performed to assess associations of score changes over time with clinical factors and dosimetric indices. RESULTS: The median neurocognitive follow-up was 3.0 years (range, 1.1-11.4 years). For the entire cohort, delayed and immediate verbal memory scaled scores demonstrated small declines. The mean decline for delayed verbal memory scores was 0.6 (P 5.01), and that for immediate verbal memory scores was 0.5 (P 5.06). Immediate and delayed visual memory scores were not found to change significantly (10.1 and -0.3, respectively; P>.30). A higher left hippocampal V 20GyE (percentage of the volume of a particular anatomical region receiving at least a 20 gray equivalent) was correlated with a score decline in all 4 measures. Female sex was found to be predictive of lower delayed verbal memory follow-up scores (P 5.035). CONCLUSIONS: Only delayed verbal memory scores were found to have declined statistically significantly at follow-up after PRT, reflecting some weakness in verbal memory retrieval. Given a correlation of left hippocampal dosimetry and memory outcomes after PRT, left hippocampal-sparing PRT plans may assist patients with pediatric brain tumors in preserving memory-retrieval abilities.
INTRODUCTION
Late neurocognitive deficits after radiotherapy (RT) in the pediatric brain tumor population are well known. 1, 2 The rapidly developing brains of younger children are at greatest risk. Learning and memory skills in particular are relevant to academic performance and translate into a greater likelihood of long-term career success. 3 Declarative memory defines the subset of memory pertaining to facts that are consciously or explicitly stored and recalled. 4 Declarative memory is encoded in the hippocampus and stored in the temporal cortex and other areas; this category can be divided further into verbal versus visual-spatial memory. 5, 6 Verbal memory is classically localized to the left temporal lobe and its associated language centers, and includes learning and recalling word lists and short stories. 7 In comparison, visual-spatial memory is localized to right medial temporal lobe structures, and includes the ability to learn and recall object shapes and spatial arrangements (eg, pictures, geometric designs). 8 Consolidation of short-term to long-term memory is driven by the hippocampi, structures that are located medially in the temporal lobes and that harbor neural progenitor cells and are known to be particularly sensitive to radiation. 5, 9 To the best of our knowledge, there have been no large series presented to date in the pediatric brain tumor literature reporting detailed memory outcomes in a cohort treated with proton RT (PRT), and reported outcomes have been mixed with respect to whether patients experienced a significant change in their verbal and visual memory skills after undergoing photon RT. 10, 11 Furthermore, dosimetric correlates of memory outcomes have been studied primarily in the adult brain tumor population, but not in the pediatric brain tumor population. 12, 13 PRT may help to mitigate the late cognitive effects of treatment through its ability to better spare normal tissues outside the target tumor volume. [14] [15] [16] [17] In the current study, we investigated verbal and visual memory outcomes after PRT in a pediatric brain tumor cohort, including clinical and region-specific radiation dosimetric correlates of cognitive outcomes. The current study was motivated by a goal of minimizing dose to critical structures affecting cognitive skills for survivors.
MATERIALS AND METHODS

Patient Cohort
Patients were eligible for inclusion in the current study if they had a primary brain tumor, were aged <22 years at the time of PRT, received PRT at the Massachusetts General Hospital (MGH) from August 2002 to September 2013, had testing of verbal and visual memory at MGH both at baseline (68 weeks of the RT start date) and at follow-up, their disease remained controlled, and dosimetry plans were available for computational analysis. A total of 70 patients comprised the study cohort. All patients had completed their treatment, including chemotherapy, at the time of follow-up with no new surgical resections or biopsies performed since their baseline evaluations. Additional clinical data were obtained via medical record review. This study was approved by the MGH institutional review board.
Radiation Planning
Our methods regarding PRT planning have been reported previously; MGH uses Proton XiO (CMS Imaging Inc, North Charleston, South Carolina). 14, [18] [19] [20] [21] 
Contouring
Neuroanatomical structures including the right temporal lobe and left temporal lobe (LTL), the right hippocampus and left hippocampus (LHC), and the whole brain were delineated manually on planning computed tomography scans using standard neuroanatomical atlases with coregistered magnetic resonance imaging guidance in MimVista 6.6.5 (Mim Software Inc, Cleveland, Ohio). Representative contours are shown in Figure 1 . Dose-volume histograms for these 5 regions were generated, and 10 dosimetric indices were calculated and used for analysis: V 20GyE , V 30GyE , V 40GyE , V 50GyE , D max , D mean , and multiple equivalent uniform dose (EUD) metrics including EUD-3, EUD-5, EUD-7, and EUD-15. 22 V 20GyE is defined as the percentage of the volume of a particular anatomical region receiving at least 20 gray equivalent (GyE). The EUD is a uniform dose delivered to a particular volume that would cause the same radiobiological effect (ie, surviving fraction of tumor cells) as the nonhomogenous dose distribution delivered in clinical practice, and the associated numbers (eg, EUD-3) represent a/b ratios implicated in the mathematical construct of the EUD. 22 
Neurocognitive Evaluations
All neuropsychological evaluations were conducted at the MGH Psychology Assessment Center by a neuropsychologist or trained psychometrist. Verbal memory was measured using the Stories subtest from the Children's Memory Scale (CMS; aged 5-16 years) or the Logical Memory subtest from the Wechsler Memory Scale (WMS)-third edition (aged > 16 years). 23, 24 Visual memory was measured with the Dot Locations subtest from the CMS or the Family Pictures subtest from the WMS-third edition. Verbal and visual memory measures each consisted of immediate (recall immediately after stimuli presented) and delayed (recall 15-25 minutes after immediate recall) conditions. Combined scores across the 2 measures were obtained to form 4 total scores: immediate verbal memory (IVeM), delayed verbal memory (DVeM), immediate visual memory (IViM), and delayed visual memory (DViM). Scaled scores (mean, 10; standard deviation, 3) were used for analysis of the memory measures. In addition, intelligence was evaluated for all patients using an ageappropriate Wechsler scale (Wechsler Preschool and Primary Scale of Intelligence-third edition, Wechsler Intelligence Scale for Children-fourth edition, or Wechsler Adult Intelligence Scale-fourth edition), yielding a full scale intelligence quotient (FSIQ) standard score (mean, 100; standard deviation, 15). [25] [26] [27] Higher scaled and standard scores reflect better performance. Only the baseline (within 3 months of receipt of RT) and most recent follow-up assessments were included in the current analysis. Medical records were reviewed for cognitive data through October 2016.
Statistical Analysis
Analysis was performed using Stata statistical software (release 14; StataCorp LP, College Station, Texas). Linear regression was used for the multivariate analysis of followup scores as a function of time elapsed since PRT, age at PRT, sex, the presence or absence of baseline neurologic symptoms (ie, posterior fossa syndrome, motor deficits, visual deficits, and hearing deficits), baseline score, and a dosimetric index. These covariates were selected based on criteria previously identified as being implicated in neurocognitive outcomes. For each memory domain, we compared several models with various dosimetric indices using Bayesian information criterion. Statistical significance was defined using an a of .05, with calculated P values below this threshold meeting the criteria for statistical significance. Table 1 summarizes the clinical characteristics that defined the patient cohort (70 patients). Of these 70 patients, 32 (46%) were enrolled in 1 of 5 prospective phase 2 PRT studies registered on ClinicalTrials.gov. [28] [29] [30] [31] [32] 
RESULTS
Patient Cohort Characteristics
Neurocognitive Performance
The median neurocognitive follow-up for the entire cohort was 3.0 years (range, 1.1-11.4 years), as calculated from the time of the baseline evaluation to the most recent follow-up neurocognitive evaluation. There were 140 neurocognitive evaluations incorporated into the analysis (70 baseline and 70 follow-up evaluations). Complete measures for each of the 4 total scores were available for all patients at baseline and at the most recent follow-up, with the exception of 3 patients who were lacking follow-up measures of IViM and DViM.
The baseline, follow-up, and change in scores for the current study cohort are summarized in Table 2 . Although a broad range of scores was observed, the current study sample performed within the average range of the test on memory measures at baseline and at follow-up. For DVeM, a mean change of -0.6 points (P 5 .01) was observed for the cohort. For IVeM, the average change was -0.5 points (P 5 .06). No statistically significant change in scores was observed for IViM (P 5 .78), DViM (P 5 .30), or FSIQ (P 5 .32). Histograms demonstrating the full score distribution for the cohort in the current study are shown in Supporting Information Figure 1 . In addition, for patients completing the same test (CMS or WMS) at baseline and at follow-up, there was no statistically significant difference in performance based on 2-tailed Student t tests comparing group means noted when these patients were compared with patients who crossed between tests (CMS to WMS) between baseline and follow-up.
Multivariate Analyses
We used multivariate linear regression on the data to develop models that could be used to predict follow-up scores for prospective patients based on clinical and dosimetric variables. The 4 models for verbal and visual memory scores are summarized as coefficients in Table 3 , and take the form of the following general equation, as shown below in equation 1:
For example, the calculated model for predicting IVeM scores is as follows in equation 2:
IVeM ðtÞ50:08ðtÞ20:02ðV 20GyE ; left hippocampusÞ 
In all 4 models, baseline memory score was found to be a significant predictor of follow-up memory scores (P<.01). Male sex was associated with higher DVeM scores (by approximately 1 point) at follow-up (P 5 .035). Higher V 20GyE to the LHC was found to be the best dosimetric correlate of worsened memory outcomes in all 4 models. However, only the dosimetric components of IVeM and DViM reached statistical significance. As a reference, the LHC dose-volume distribution for all patients as a function of all 4 memory scores, dichotomized into declined versus improved/stable scores, is illustrated in Supporting Information Figure 2 .
In addition, we considered adding a specific component for CSI dose in the multivariate models. However, the mean LHC dose in patients who received CSI was 38.5 GyE, and was 14.2 GyE for those who did not receive CSI. This was a statistically significant difference (P<.001). As such, a second dosimetric component related to CSI (eg, whole-brain dosimetric indices) would be too highly linked with other dosimetric variables (eg, LHC dose) and thus would be statistically impractical to include.
DISCUSSION
To the best of our knowledge, the current study is among the largest reports of verbal and visual memory outcomes after RT for patients with pediatric brain tumors reported to date, and the first report after PRT. Overall, the cohort performed within the normal range of these measures at follow-up. The greatest decline that was observed (mean change of -0.6 in DVeM), although statistically significant, was not clinically meaningful, thereby indicating promising outcomes for these patients treated with PRT. We further demonstrated a significant association between the volume of LHC receiving 20 GyE (V 20GyE ) and verbal memory decline. Therefore, when possible, the LHC should be relatively spared during the administration of RT to help to limit declines in the DVeM score compared with peers over time (it should be noted that a decline in scaled scores typically represents slower growth in skills over time rather than an actual loss of skills). Given that language skills have been primarily mapped to left (dominant) hemisphere structures, including the left hippocampus, this finding for verbal memory is consistent with our previous understanding of functional neuroanatomy. 33 To our knowledge, previously reported learning and memory outcomes after photon RT for patients with pediatric brain tumors have been mixed, but were insufficiently robust to conclusively correlate structural dose with neurocognitive decline. Table 4 summarizes several of these studies juxtaposed with the findings of the current study. 10, 11, 34, 35 Reports by Nagel et al and Margelisch et al assessed the neurocognitive abilities of patients with brain tumors in a cross-sectional fashion (ie, at a single time point), and both studies observed worse performance on measures of verbal learning and memory skills in patients with brain tumors compared with control patients. 11, 34 In comparison, reports by Di Pinto et al and Spiegler et al involved following patients with pediatric brain tumors longitudinally and tracking changes in learning and memory skills between baseline and followup. 10, 35 Di Pinto et al reported that female sex, the need for ventriculoperitoneal shunt placement, and chemotherapy exposure before receipt of RT were predictive of lower scores. Overall, their study cohort had either stable or improved verbal or visual learning scores, but Di Pinto et al did not include a dosimetric analysis of specific brain regions, and only included those patients who required tumor bed irradiation. 10 No child received CSI, and therefore we would expect that doses to the LHC in this cohort generally would be lower than in the current study cohort, approximately 50% of whom were treated with a CSI component. A smaller study by Spiegler et al reported neurocognitive outcomes in a cohort of 34 patients with posterior fossa tumors, primarily medulloblastoma. 35 For the 9 patients for whom memory scores were available, the authors found on mixed model regression analysis that verbal memory standard scores did not significantly decline (slope of 1 0.45 points/year; standard error, 1.59), whereas visual memory standard scores did decline (slope of -2.8 points/year; standard error, 1.18). 35 Again, no RT dosimetric analysis was performed. In addition, the analysis performed herein demonstrated a propensity for female patients to score slightly lower than male patients, which is consistent with previous findings by Di Pinto et al. 10 We also found that the dose to a larger volume of the LHC correlated with reduced verbal memory retrieval at follow-up. To our knowledge to date, work investigating the relationship between hippocampal dosimetry and memory has been reported primarily in the adult population after photon RT. The Radiation Therapy Oncology Group (RTOG) 0933 trial studied the effects of wholebrain RT that avoided the hippocampus for a cohort of adult patients with brain metastases. They found this treatment modality was associated with the preservation of verbal memory and an improved quality of life. 12 In addition, Peiffer et al reported that V 60Gy to the LTL and LHC each correlated with poorer verbal delayed recall performance with a change in variance (Dr 2 ) > 0.1, and V 40Gy to the LTL correlated with poorer verbal immediate recall performance with similar confidence. 13 Furthermore, Hsiao et al reported that a V 60Gy > 10% to temporal lobes was associated with a greater reduction in cognitive functioning, including memory. 36 In contrast to the adult literature, the results of the current study found that the lower-dose dosimetric indices, specifically V 20GyE , correlated best with memory outcomes. However, we did find that other left hippocampal dosimetric indices (eg, D max , D mean ) also were highly correlated. This indicates that the LHC dose can have a continuous effect and should be minimized when possible to maximize learning and memory outcomes. The LHC resides in the LTL, and dose to the LTL also has been found to be frequently correlated with FSIQ outcomes. 18, [37] [38] [39] The results of the current study demonstrated that, for memory scores, the LHC specifically correlated more frequently rather than the LTL. The current study has some limitations. For example, although many patients were followed on trials prospectively, this particular analysis was conducted in a retrospective fashion. Second, the multivariate regression models presented herein have not yet been externally validated and are designed based on the study population presented in the current study. In addition, the median length of neurocognitive follow-up in the current study cohort was 3.0 years, which may appear to be shorter than other peer studies cited above. However, our follow-up time calculation was done from the time of the baseline evaluation, whereas some studies report the follow-up from the time of diagnosis (often because not all patients included have baseline evaluations), and others report clinical follow-up only. 10, 35 Standardizing these practices will help to simplify direct comparisons across the literature.
To the best of our knowledge, the current study is the first report of dosimetric correlates with verbal and visual memory skills in patients with pediatric brain tumors and the first report of these outcomes in a pediatric cohort treated with PRT. In the current study cohort, patients' memory scores remained within the average range for the tests and were effectively stable at follow-up. However, we observed that female patients were more likely to perform worse in verbal memory than male patients, and we demonstrated a correlation with V 20GyE to the left hippocampus and a decline in function in some patients. To this end, we developed models with key clinical and dosimetric factors to best predict which patients will experience a decline.
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